Prakt. lékáren. 2011; 7(4): 158-159

Denosumab

Petr Hrdý, Pavel Novosad
Osteocentrum, MEDIEKOS Labor s.r.o., Zlín

Denosumab is a fully human recombinant monoclonal antibody (IgG2), that inhibits bone resorption by blocking receptor activator of

nuclear factor kappaB ligand (RANK ligand, RANKL), which is the key mediator of function, formation and surviving of osteoclasts. Therapy

of denosumab leads to risk reduction of vertebral and nonvertebral fractures the same way as fractures of proximal femur, which was demonstrated

in big multicentric study against the placebo (study FREEDOM). As well the therapy of denosumab leads to significant rising of

BMD in compare to active drug (studies DECIDE and STAND). Denosumab is administered parenteral, once every 6 months via subcutaneous

injection of 60 mg dose, that may improve adherence to treatment of osteoporosis in comparation with other osteoporosis treatment.

Keywords: denosumab, osteoporosis, RANK ligand

Published: August 10, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrdý P, Novosad P. Denosumab. Praktické lékárenství. 2011;7(4):158-159.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone 2001; 28(2): 208-214. Go to original source... Go to PubMed...
    2. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79(5-6): 243-253. Go to original source... Go to PubMed...
    3. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16(2): 348-360. Go to original source... Go to PubMed...
    4. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361(8): 756-765. Go to original source... Go to PubMed...
    5. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008; 43(2): 222-229. Go to original source... Go to PubMed...
    6. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93(6): 2149-57. Go to original source... Go to PubMed...
    7. Rancher TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. The Lancet 2011; 377(9773): 1276-1287. Go to original source... Go to PubMed...
    8. www.xgeva.com/oncology.html [cit.2011/03/21].

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.